BACKGROUND: Overtreatment is a common concern for patients with ductal carcinoma in situ (DCIS), but this entity is difficult to distinguish from invasive breast cancers in administrative claims data sets because DCIS often is coded as invasive breast cancer. Therefore, the authors developed and validated algorithms to select DCIS cases from administrative claims data to enable outcomes research in this type of data. METHODS: This retrospective cohort using invasive breast cancer and DCIS cases included women aged 66 to 70 years in the 2004 through 2011 Texas Cancer Registry (TCR) data linked to Medicare administrative claims data. TCR records were used as "gold" standards to evaluate the sensitivity, specificity, and positive predictive value (PPV) of 2 algorithms. Women with a biopsy enrolled in Medicare parts A and B at 12 months before and 6 months after their first biopsy without a second incident diagnosis of DCIS or invasive breast cancer within 12 months in the TCR were included. Women in 2010 Medicare data were selected to test the algorithms in a general sample. RESULTS: In the TCR data set, a total of 6907 cases met inclusion criteria, with 1244 DCIS cases. The first algorithm had a sensitivity of 79%, a specificity of 89%, and a PPV of 62%. The second algorithm had a sensitivity of 50%, a specificity of 97%. and a PPV of 77%. Among women in the general sample, the specificity was high and the sensitivity was similar for both algorithms. However, the PPV was approximately 6% to 7% lower. CONCLUSIONS: DCIS frequently is miscoded as invasive breast cancer, and thus the proposed algorithms are useful to examine DCIS outcomes using data sets not linked to cancer registries. Cancer 2018;124:2815-23.
INTRODUCTION
Medical administrative claims data are increasingly being used to examine cancer-related outcomes in the United States. Algorithms developed to identify cases of breast cancer in Medicare claims data have been identified and compared.
1 Previous algorithms also have been developed that identify different stages of breast cancer, but to the best of our knowledge none specifically differentiate ductal carcinoma in situ (DCIS) from other breast cancer stages, and may list DCIS diagnoses as an exclusion criterion. 2 It is important to understand how different treatments affect outcomes for patients with DCIS. DCIS has been recognized as a potential source of overtreatment because, to our knowledge, it currently is unknown how to determine whether it will progress to invasive disease. 3, 4 Women also are concerned about disease recurrence, which has been linked to worry and a lower quality of life for patients with breast cancer. 5 DCIS represents approximately 20% of breast cancers that are identified through mammography screening. 6 To examine treatment outcomes in populations with this early-stage cancer, data that can detail treatment and outcomes are needed.
Cancer registries are excellent sources of information regarding cancer staging, but often lack data concerning longterm outcomes, such as the late effects of treatment, cancer recurrence, and patient-reported outcomes. Cancer registries that have been linked to specific groups of patients, such as those enrolled in Medicare and Medicaid, provide an excellent opportunity to develop algorithms that can be applied to claims data that cannot be readily linked to cancer registries.
Although DCIS has a separate International Classification of Diseases, Ninth Revision (ICD-9) code (233.0) for diagnosis, we have noted it often is miscoded as breast cancer (174.X), thereby making it difficult to differentiate between the 2 groups. This issue is of concern for researchers who use billing claims to evaluate outcomes because it can adversely affect population research in samples that cannot be linked to cancer registries.
Misclassifying early-stage invasive breast cancer in outcomes research as DCIS may inflate mortality and recurrence estimates associated with DCIS, leading to possible erroneous conclusions regarding overtreatment as well as the cost and benefits of treatment. In addition, misclassifying DCIS cases as invasive cancer can lead to an underestimation of treatment costs. Several algorithms have been published that identify breast cancer, and can differentiate stages through differences in treatment after diagnosis.
1,2,7,8 However, due to the fact that it has been recommended to treat DCIS similarly to stage I breast cancer in some cases, 9 it is difficult to differentiate DCIS from early-stage invasive breast cancer using medical claims codes for treatment if the data cannot be linked to cancer registries. To conduct outcomes research using other sources of medical claims data, it is necessary to develop an algorithm that can determine DCIS diagnoses accurately.
To address the problem of miscoding DCIS, we aimed to develop algorithms that could be used to differentiate between women with a true DCIS diagnosis and those diagnosed with invasive breast cancer using cancer registry data linked to Medicare claims data. We developed two 5-step algorithms based on how DCIS cases progress through biopsy to treatment, and compared the performance of the algorithms to evaluate their ability to sensitively and specifically identify patients with true primary diagnoses of DCIS, as well as how well they identify cases from a general sample of Medicare enrollees.
MATERIALS AND METHODS
Algorithms were developed using retrospective data from the Texas Cancer Registry (TCR) and linked Medicare claims data between 2004 and 2012. The TCR is a surveillance data set that consists of reports of all diagnosed cancer cases and cancer stages in the state of Texas.
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These data were used as the reference data to identify confirmed cases and stages of breast cancer. Medicare data consist of all medical claims from adults aged 65 years. These data include Medicare Provider Analysis and Review (MEDPAR) files, Outpatient Standard Analytical Files, durable medical equipment records to more fully examine whether chemotherapy treatment was administered, and Medicare carrier files. These files allowed us to obtain information regarding inpatient hospital stays, outpatient services, and services from medical professionals. Data sets were linked in collaboration with the National Cancer Institute. The linkage between the TCR and Medicare used probabilistic linkage methods to protect patient privacy. All data have been deidentified to prevent the identification of patients' health information. This study was exempted from review by the University of Texas Medical Branch institutional review board.
All women who were recorded in the TCR and were enrolled in Medicare were eligible. For the purposes of the current study, DCIS will refer to stage 0 breast cancer, and "invasive breast cancer" will refer to all other stages of breast cancer. Eligibility requirements for inclusion in the cancer cohort were: 1) female with DCIS or invasive breast cancer diagnosed between 2005 and 2011, with a primary cancer that was not identified only through autopsy or the death certificate; 2) aged 66 to 70 years at the time of diagnosis; 3) underwent a breast biopsy between 2005 and 2011; 4) had complete Medicare parts A and B coverage 12 months before and 6 months after the first biopsy; and 5) did not develop a second incident breast cancer within 12 months of the initial diagnosis (see Supporting Fig. 1 ). We did not include cases of invasive breast cancer with DCIS as a secondary cancer within 12 months of the breast cancer diagnosis, and we also excluded DCIS cases with invasive breast cancer as a secondary cancer within 12 months of the diagnosis of DCIS. These exclusions were applied because the diagnosis and treatment codes entered into the claims data set for their condition may be different from the standard care for DCIS. We used ICD-9 codes 233.0 for DCIS and 174.X for invasive breast cancer. Alternate ICD-10 codes that will be valuable for testing these algorithms in the future also have been included (see Supporting Table 1 ).
We included women aged 70 years because after that age, guidelines are less clear regarding whether mammography screening should be used routinely, and thus including older women may have biased the sample. Race/ethnicity were determined using the variables from the TCR data. We used TCR data for this variable rather than Medicare variables because Medicare did not distinguish between Hispanic white and non-Hispanic white individuals before 2006. Of the 6907 selected subjects, approximately two-thirds (4604 subjects) were randomly selected into the training data set, which was used for algorithm development. The remaining data, in the data set Original Article that is referred to as the validation data set, were used for algorithm validation.
Among the 6907 selected subjects, 1244 were cases of DCIS. To evaluate the frequency of miscoding, we examined the percentage of these subjects with diagnoses of invasive breast cancer (code 174.X) on their Medicare claims within 90 days after biopsy.
To test the algorithms in a general sample of women, we used 100% Texas Medicare data from 2010 linked to the TCR (general population cohort). We selected female beneficiaries with complete Medicare parts A and B enrollment in the index year (2010), 12 months before the index year, and at least 6 months after the index year. Women in this sample also needed to be alive on June 30, 2011. From this sample, we selected those who were aged 66 to 70 years as of January 1, 2010. This resulted in 242,960 total beneficiaries (see Supporting Fig. 2) who were eligible for this portion of the validation study. Their breast cancer diagnoses (DCIS or other breast cancer stages) were determined using TCR data. Race/ethnicity and Medicaid eligibility were determined from Medicare enrollment records. The median zip code household income was obtained from the 5-year American Community Survey that was conducted between 2007 and 2011.
Algorithm Development
Based on the clinical process of breast cancer diagnosis and treatment provided by a breast cancer medical oncologist, radiation oncologist, and surgeon (coauthors), we developed a logical model of the steps a patient must go through from biopsy to treatment for both DCIS and invasive breast cancer. Using this logic, we considered the differences in the trajectory of care from biopsy through treatment that a patient with DCIS would receive compared with other patients with breast cancer. We did not use DCIS-targeted treatment as a step in these algorithms because treatment may be similar for patients with DCIS and early-stage breast cancer. Treatment was used only to differentiate patients with advanced cancer from those with DCIS.
Two algorithms were developed that included 5 steps to identify DCIS cases using claims data. The cancer diagnosis from the TCR was considered the "gold standard" and the algorithm determined the "test positive." The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated at each step for both algorithms. The first algorithm that was assessed detected DCIS cases through 5 steps that were applied to the Medicare data of the selected patients with breast cancer, including: 1) women must have undergone a breast biopsy between 2005 and 2011; 2) they must have had a claim with DCIS as the primary diagnosis from a general surgeon, pathologist, diagnostic radiologist, clinical laboratory, hematologist, or an oncologist within 90 days after the biopsy was obtained; 3) all patients with axillary lymph node involvement within 90 days of biopsy were not considered to be patients with DCIS; 4) women with a personal history of invasive breast cancer in the previous year were not considered to be patients with DCIS; and 5) those who received advanced treatment, such as chemotherapy or mastectomy with radiotherapy in the 6 months after biopsy, also were not considered to be patients with DCIS. All codes used to identify cases in each step are included in the footnotes of the tables that show the results of the algorithms, and the codes for radiotherapy and mastectomy were determined using those previously identified in the literature. 11 For the second algorithm, the steps were identical, with the exception of the second step, for which cases needed to have at least 1 inpatient or 2 outpatient/physician claims with DCIS as the primary diagnosis within 90 days after biopsy, regardless of provider type. The 2 outpatient/physician claims needed to be separated by at least 30 days. This was done to increase the specificity and PPV. The primary diagnoses could have included visits to a provider to discuss the course of action for the DCIS or any other service that was given primarily for DCIS. This algorithm may not have captured as many women who had chosen to watch and wait or who had significant comorbidities or frailty that limited their treatment options. When validating the algorithms using the general sample of Texas Medicare enrollees, the first step was to identify women who had undergone a breast biopsy in 2010. For each algorithm, we performed a logistic regression model in which the test result was used to predict the true cancer diagnosis. The area under the receiving operating characteristic curve (AUC) was estimated from the model to indicate how well the model discriminated between patients with DCIS and other patients.
Algorithm Validation
We examined how the algorithms performed in the validation data set of the cancer cohort using sensitivity, specificity, PPV, NPV, and AUC measures. In addition, we evaluated the performance of the algorithms in the general population cohort, consisting of women aged 66 to 70 years from the 2010 Texas Medicare data. All analyses were conducted using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina).
RESULTS
Of 56,635 women with DCIS or invasive breast cancer as their primary cancer, 6907 women met the inclusion criteria and were included in the cancer cohort (see Supporting Fig. 1 ). Of these, 1244 were DCIS cases. We found that approximately 89% of patients with DCIS had at least 1 Medicare claim with invasive breast cancer listed as a primary diagnosis within 90 days after biopsy. Among the women in the cancer cohort, 4604 were randomly assigned to the training data set and 2303 were included in the validation data set ( Table 1 ). The distributions of women by race/ethnicity, Medicaid eligibility, mean age, and median zip code household income were similar between the data sets.
The first algorithm had a sensitivity of 79.2%, a specificity of 89.2%, a PPV of 62.2%, and a NPV of 95% among women from the cancer cohort included in the training subsample ( Table 2 ). The second algorithm had a lower sensitivity of 50.4%, but yielded a higher specificity (96.6%) and PPV (77.0%). The AUCs were 0.842 (95% confidence limits, 0.828-0.857) for the first algorithm and 0.735 (95% confidence limits, 0.718-0.752) for the second algorithm. The results for both algorithms were similar among the cancer cohort in both the training and validation data sets (Table 3) .
In the general population cohort (see Supporting  Fig. 2 ), 203 patients had been diagnosed with DCIS according to the TCR (see Supporting Table 2 ). More advanced stages of breast cancer had been diagnosed in 766 women, leaving the majority (99.6%) without a breast cancer diagnosis. Nearly 75% of the sample was white, followed by 16% Hispanic and 8% black. The mean household income by zip code was $54,040.
The results for algorithm 1 compared favorably in the general population cohort with those results derived from the cancer cohort (Table 4) . A total of 292 enrollees "tested" positive, resulting in a sensitivity of 79.3%, a specificity of 99.9%, and an NPV of 100%. Algorithm 2 results obtained in the general population cohort also compared favorably with its performance in the cancer cohort. A total of 149 participants "tested" positive, leaving a sensitivity of 52.2%, a specificity of 100%, and an NPV of 100%. However, the PPV was approximately 6% to 7% lower for both algorithms in the general population sample compared with the algorithm performance in the cancer cohort (55.1% and 71%, respectively, for algorithms 1 and 2,).
DISCUSSION
Although DCIS has its own ICD-9 diagnosis code (233.0), it often is coded incorrectly, making it necessary to develop an algorithm for studies that will not use cancer registry-linked data. In fact, we found that it was miscoded at least once as invasive cancer for 89% of the patients with DCIS in the current study cancer cohort sample during the 90-day period after biopsy. The need , 79900, 0073T, 0182T, 0190T, 0197T, A4650, A9527, C1715, C1716, C1717, C1718, C1719, C1728, C1879, C2616, C2634, C2635, C2636, C2637, C2638, C2639, C2640, C2641, C2642, C2643, C2644, C2645, C2646, C2647, C2648, C2649, C2650, C2651, C2652, C2653, C2654, C2655, C2656, C2657, C2658, C2659, C2660, C2661, C2662, C2663, C2664, C2665, C2666, C2667, C2668, C2669, C2670, C2671, C2672, C2673, C2674, C2675, C2676, C2677, C2678, C2679, C2680, C2681, C2682, C2683, C2684, C2685, C2686, C2687, C2688, C2689, C2690, C2691, C2692, C2693, C2694, C2695, C2696, C2697, C2698, C2698, C2699, C2699, C9714, C9715, C9725, C9726, C9728, G0173, G0174, G0251, G0339, G0340, Q3001, S8030, and 77761 to 77799. HCPCS codes for chemotherapy included C9415, J9000 to J9002, Q2048 to Q2050, C9420, C9421, J9070, J9080, J9090 to J9097, C9127, C9431, J9264, J9265, J9267, J9170, J9171, J9250, J9260, J9190, J9178, C9131, J9354, J9355, C9292, J9306, J9045, J8520, J8521, J9201, C9440, J9390, C9418, J9060, J9062, C9240, J9207, C9214, C9257, J9035, Q2024, and S0116. Mastectomy ICD-9 code: 85.4 and mastectomy CPT codes : 19180, 19182, 19200, 19220, 19240 , and 19303 to 19307. to study outcomes questions is apparent in the literature. A recent review noted the need for research that can help physicians to better select which patients can forgo radiotherapy safely, and whether short-course radiotherapy may be a better option than endocrine therapy. 12 Although the answers to research questions using data not linked to cancer registries or medical records may be limited due to a lack of information regarding surgical margin status, hormone receptor status, tumor grade, or other details found in cancer registries, it does allow for population-level investigation in a broader sense.
Investigating these issues, particularly among younger women, is of increasing relevance. Younger women with DCIS are more frequently choosing mastectomy, for example, as treatment. 13 Understanding the ramifications of these changes in treatment in terms of survival, overtreatment, and patient outcomes are critical for determining whether clinical practice should be adjusted. Much of the data needed to evaluate outcomes related to mastectomy at a younger age may be readily available. However, the effective selection of DCIS cases in data that include populations of young women with long-term outcomes to investigate these questions is needed.
The algorithms in the current study offer 2 solutions to the issue of differentiating between invasive breast cancer and DCIS. The first algorithm uses a step that is more sensitive and less restrictive. This algorithm, which requires a DCIS diagnosis coded by providers who practice a specialty that is responsible for the diagnosis of DCIS, would be appropriate for studies examining the incidence of DCIS or other population-level examinations of this condition. State and national cancer registries remain the gold standard, but they often lack detail that frequently can be found in administrative claims data. Furthermore, they often are restricted to geographical areas, such as states, or other participating regions, and requirements may not always be similar for inclusion across registries. The algorithms herein also allow for the examination of DCIS across time in Medicare data, including years in which Surveillance, Epidemiology, and End Results (SEER) cancer registry program coverage areas were smaller, or for areas of the United States that did not participate in SEER continuously.
14 It also allows for the examination of response to changing policy or recommendations related to the detection and treatment of DCIS within the United States or between different regions of the United States using Medicare records not linked to SEER. Although linkages between Medicare and these registries are powerful tools with which to be able to examine cancer treatment and outcomes, there is less of an ability to examine similar topics among populations aged <65 years. More efforts are needed to validate these algorithms among younger women. For example, linkages between Medicaid data sets and state cancer registries or administrative claims data linked to electronic medical records could be used to validate these algorithms in younger women.
The second algorithm, which is more restrictive but highly specific and has an improved PPV, would be more appropriate for the examination of treatment practices and outcomes because it removes cases that are less likely to be true DCIS cases. This algorithm disregards the diagnosing practitioner's specialty in favor of more frequent listing of DCIS diagnoses. Having a more specific algorithm allows for greater assurance that the diagnoses that are being captured actually are DCIS cases, which will allow for the more accurate assessment of outcomes. The effectiveness of treatments, such as a reduction in the recurrence of any stage of breast cancer and long-term effects related to therapy, is particularly important for patients with DCIS because DCIS often is detected with mammography, particularly with the computer-aided detection methods that are becoming more commonly used, 15 but not all cases progress to invasive disease. The study of DCIS treatment outcomes is more important than ever to better understand the benefits and harms of different treatments among women diagnosed with these conditions.
Other algorithms that have been developed to detect a breast cancer case after screening mammography have shown high sensitivity, specificity, PPV, and NPV. 16 In a systematic review of the ability of 3 algorithms to detect breast cancer cases, the sensitivity of the algorithms ranged from 62% to 90%, whereas the specificity was much higher and was reported to be >99%.
1 However, these algorithms did not perform quite as well when tested on later data, with sensitivity ranging from 59% to 80% for 1995 and 1998 data.
1 None of the algorithms were developed to detect DCIS cases. Although our algorithms have relatively lower sensitivity and specificity compared with those that were developed to detect breast cancer cases in claims data sets, to the best of our knowledge they are the first known algorithms developed specifically to differentiate DCIS from other breast cancer stages.
Both algorithms performed comparably well in a sample of Medicare enrollees aged 66 to 70 years. These results indicate that these algorithms could be used in a general sample from administrative claims data and achieve results that are similar to when it is used in a sample of only women who had been diagnosed with breast cancer. We calculated that approximately 0.4% of the general population sample had an incident cancer, compared with the age-adjusted rate of 0.2% reported among all age groups between 2004 and 2010 in analyses performed using SEER data. 17 The higher rate reported herein likely is due to the fact that the current study sample included only older women. Close to one-half of all new breast cancer cases diagnosed in the United States occur among women aged 65 years. 18 As coders have moved to the ICD-10 system (code D05.1x for DCIS), we expect that the difficulties in coding DCIS as noninvasive disease will continue. The ICD-10 code for malignant neoplasms of the breast is C50.xxx. Although these codes are more specific, they are not billable codes, and therefore providers have little incentive to code accurately every time they see a patient. Therefore, it is likely that the current algorithm will need to be tested in the future using ICD-10 coding when cancer registry data linkages are updated to include recent administrative data. Health care providers were required to switch to ICD-10 codes in October 2015. Unfortunately, to the best of our knowledge, Medicare data linked to the TCR and SEER registries for that time period are not currently available in the United States, and therefore this algorithm will need to be tested when those data are available. However, the information from the current study still will be valuable because it is important to evaluate how treatment and related outcomes change across time. Therefore, using the current algorithm on data with ICD-9 codes and extending the period of evaluation into records using ICD-10 codes will make it easier for researchers who would like to conduct these types of investigations.
There were some limitations to the current study. The study was conducted only among Medicare users aged 66 to 70 years and thus the algorithms may behave differently among younger women or older women. However, it is unlikely that providers change their coding practices depending on the age of their patients. It also is possible that the results of the current study would be different if applied to a national sample because cancer diagnostic practices may be more variable in a national sample. Future research is needed to evaluate the possibility of detecting a false-positive result for DCIS when invasive breast cancer and DCIS cases are selected from a data set containing women from younger age groups. Furthermore, the patients included in the current study were fee-for-service Medicare enrollees, which may not be generalizable to other Medicare populations. Patients under this plan may demonstrate differences in how they seek care or follow-up treatment compared with those with managed care plans. Finally, it is likely that algorithm 2 would underestimate the incidence of DCIS in large populations.
The 2 algorithms in the current study that were developed have differing sensitivities, specificities, and PPVs that can be used to differentiate DCIS status among women with any stage of breast cancer. The algorithm that has a higher sensitivity can be used to evaluate populationlevel estimates of DCIS. The second algorithm has a high specificity and PPV, which make it more appropriate for conducting outcomes research, such as comparing treatments or patient safety. These algorithms can be used to examine changes in DCIS detection and treatment in the United States using existing observational data.
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